+91 888 589 6523CONTACT US
0item(s)

You have no items in your shopping cart.

Product was successfully added to your shopping cart.

Apixaban- Drug Molecule Intelligence (66 Countries)

Details

Apixaban- Drug Molecule Intelligence report provides comprehensive data on product information, application areas, manufacturing methods, formulation details, regulatory approval, data exclusivity, generic launch constrained date, market trends, manufacturers and suppliers details.

The report also provides key patents, extension, and data exclusivity expiry for 66 countries, regulatory issues and key players. The report covers patent information and data exclusivity covering 66 countries, including extension details (SPC and national law) for 30 European countries, Australia, Canada, Israel, Japan and the USA.

The report covers the Market Assessment of the Apixaban covering the historical global sales and also provides the Apixaban sales estimation during the forecasted period (2017-2021). 

Country Coverage:  

  • Albania
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Bosnia & Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • Former Yugoslav Republic of Macedonia
  • France
  • Germany
  • Great Britain
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malaysia
  • Malta
  • Mexico
  • Monaco
  • Montenegro
  • The Netherlands
  • New Zealand
  • Norway
  • Philippines
  • Poland
  • Portugal
  • Romania
  • Russia
  • San Marino
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • Turkey
  • Ukraine
  • Uruguay
  • USA
  • Viet Nam

Details

1. Introduction
2. General Drug Product Information
2.1. Product Summary
2.2. Indications
2.3. Route of Synthesis
2.4. Dosage & Administration
2.5. Physico-chemical Properties
2.6. Pharmacology
2.7. Pharmacokinetic Properties
2.8. Pharmacodynamics
2.9. Mechanism of Action
2.10. Adverse Reactions
2.11. Supply & Storage
2.12. Drug History
3. Market Analysis
3.1. Historical Sales
3.2. Forecasted Sales
3.3. Market Competition
3.3.1. Intra-molecule completion
3.3.2. Intra-therapeutic class competition
4. API Manufacturers & DMF Holders
4.1. US DMF Holders
4.2. European DMF (CEP)
4.3. DMF from other territories
4.4. API Manufacturers by Country
4.5. API Manufacturers by Region
5. Drug Approval & Data Exclusivity
6. Key Patents
7. Key Patents family and their expiry with PTE & SPC
7.1. Product Patents
7.2. Method of Use Patents
7.3. Composition Patents
8. High Level Summary of the Key Patents
9. Legal Proceedings
9.1. Product litigation
9.2. Patent litigation
9.2.1. Post Grant Proceeding
9.2.2. Patent Challenges
10. Generic Entry
11. Clinical Trails
12. Conclusion
13. About IBRSoluTions
14. Contact Us
15. Disclaimer

Details

Tables:

  • Product summary
  • Historical sales data
  • Forecasted sales data
  • US DMF holder
  • EU COS holder
  • Drug approval and exclusivity
  • Patent family details

Figures:

  • Innovator product
  • Packaging details
  • Sales data analysis
  • API manufacturer distribution

Additional Information

Report Code DMIAPI66
Published On Sep 4, 2017
No. of pages 45
Countries Worldwide
Therapeutic Class Hematologic diseases

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

  1. Be the first to review this product

Write Your Own Review

Only registered users can write reviews. Please, log in or register

$999.00